{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:31:33Z","timestamp":1793284293532,"version":"4.5.0"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["75F40120C00085"],"award-info":[{"award-number":["75F40120C00085"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Neutralisation assays are commonly used to assess vaccine-induced and naturally acquired immune responses; identify correlates of protection; and inform important decisions on the screening, development, and use of therapeutic antibodies. Neutralisation assays are useful tools that provide the gold standard for measuring the potency of neutralising antibodies, but they are not without limitations. Common methods such as the heat-inactivation of plasma samples prior to neutralisation assays, or the use of anticoagulants such as EDTA for blood collection, can inactivate the complement system. Even in non-heat-inactivated samples, the levels of complement activity can vary between samples. This can significantly impact the conclusions regarding neutralising antibody potency. Restoration of the complement system in these samples can be achieved using an exogenous source of plasma with preserved complement activity or with purified complement proteins. This can significantly enhance the neutralisation titres for some antibodies depending on characteristics such as antibody isotype and the epitope they bind, enable neutralisation with otherwise non-neutralising antibodies, and demonstrate a better relationship between in vitro and in vivo findings. In this review, we discuss the evidence for complement-mediated enhancement of antibody neutralisation against a range of viruses, explore the potential mechanisms which underpin this enhancement, highlight current gaps in the literature, and provide a brief summary of considerations for adopting this approach in future research applications.<\/jats:p>","DOI":"10.1007\/s00018-023-05074-2","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T04:43:05Z","timestamp":1704948185000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Direct enhancement of viral neutralising antibody potency by the complement system: a largely forgotten phenomenon"],"prefix":"10.1007","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7761-8341","authenticated-orcid":false,"given":"Jack","family":"Mellors","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,11]]},"reference":[{"key":"5074_CR1","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1128\/CVI.00644-12","volume":"20","author":"TJ Gardner","year":"2013","unstructured":"Gardner TJ, Bolovan-Fritts C, Teng MW et al (2013) Development of a high-throughput assay to measure the neutralization capability of anti-cytomegalovirus antibodies. Clin Vaccine Immunol 20:540\u2013550. https:\/\/doi.org\/10.1128\/CVI.00644-12","journal-title":"Clin Vaccine Immunol"},{"key":"5074_CR2","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41577-021-00542-x","volume":"21","author":"PC Taylor","year":"2021","unstructured":"Taylor PC, Adams AC, Hufford MM et al (2021) Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol 21:382\u2013393. https:\/\/doi.org\/10.1038\/s41577-021-00542-x","journal-title":"Nat Rev Immunol"},{"key":"5074_CR3","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.3201\/eid2808.220584","volume":"28","author":"EF de Oliveira-Filho","year":"2022","unstructured":"de Oliveira-Filho EF, Rincon-Orozco B, Jones-Cifuentes N et al (2022) Effectiveness of naturally acquired and vaccine-induced immune responses to SARS-CoV-2 mu variant. Emerg Infect Dis 28:1708\u20131712. https:\/\/doi.org\/10.3201\/eid2808.220584","journal-title":"Emerg Infect Dis"},{"key":"5074_CR4","doi-asserted-by":"publisher","first-page":"eade9078","DOI":"10.1126\/scitranslmed.ade9078","volume":"15","author":"D Benkeser","year":"2023","unstructured":"Benkeser D, Montefiori DC, McDermott AB et al (2023) Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial. Sci Transl Med 15:eade9078. https:\/\/doi.org\/10.1126\/scitranslmed.ade9078","journal-title":"Sci Transl Med"},{"key":"5074_CR5","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41579-022-00809-7","volume":"21","author":"M Cox","year":"2023","unstructured":"Cox M, Peacock TP, Harvey WT et al (2023) SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies. Nat Rev Microbiol 21:112\u2013124. https:\/\/doi.org\/10.1038\/s41579-022-00809-7","journal-title":"Nat Rev Microbiol"},{"key":"5074_CR6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1385\/1-59259-017-9:113","volume-title":"Therapeutic interventions in the complement system","author":"RA Wetsel","year":"2000","unstructured":"Wetsel RA, Kildsgaard J, Haviland DL (2000) Complement anaphylatoxins (C3a, C4a, C5a) and their receptors (C3aR, C5aR\/CD88) as therapeutic targets in inflammation. In: Lambris JD, Holers VM (eds) Therapeutic interventions in the complement system. Humana Press, Totowa, pp 113\u2013153"},{"key":"5074_CR7","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/0165-2478(89)90022-9","volume":"21","author":"JD Fingeroth","year":"1989","unstructured":"Fingeroth JD, Heath ME, Ambrosino DM (1989) Proliferation of resting B cells is modulated by CR2 and CR1. Immunol Lett 21:291\u2013301","journal-title":"Immunol Lett"},{"key":"5074_CR8","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.imlet.2012.02.003","volume":"143","author":"K T\u00f6r\u00f6k","year":"2012","unstructured":"T\u00f6r\u00f6k K, Kremlitzka M, S\u00e1ndor N et al (2012) Human T cell derived, cell-bound complement iC3b is integrally involved in T cell activation. Immunol Lett 143:131\u2013136. https:\/\/doi.org\/10.1016\/j.imlet.2012.02.003","journal-title":"Immunol Lett"},{"key":"5074_CR9","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1089\/088922204322996563","volume":"20","author":"H Ying","year":"2004","unstructured":"Ying H, Ji X, Hart ML et al (2004) Interaction of mannose-binding lectin with HIV type 1 is sufficient for virus opsonization but not neutralization. AIDS Res Hum Retroviruses 20:327\u2013335. https:\/\/doi.org\/10.1089\/088922204322996563","journal-title":"AIDS Res Hum Retroviruses"},{"key":"5074_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023542","volume":"6","author":"V Tjomsland","year":"2011","unstructured":"Tjomsland V, Elleg\u00e5rd R, Che K et al (2011) Complement opsonization of HIV-1 enhances the uptake by dendritic cells and involves the endocytic lectin and integrin receptor families. PLoS ONE 6:e23542. https:\/\/doi.org\/10.1371\/journal.pone.0023542","journal-title":"PLoS ONE"},{"key":"5074_CR11","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.virol.2008.03.022","volume":"376","author":"JB Johnson","year":"2008","unstructured":"Johnson JB, Capraro GA, Parks GD (2008) Differential mechanisms of complement-mediated neutralization of the closely related paramyxoviruses simian virus 5 and mumps virus. Virology 376:112\u2013123. https:\/\/doi.org\/10.1016\/j.virol.2008.03.022","journal-title":"Virology"},{"key":"5074_CR12","doi-asserted-by":"publisher","first-page":"13463","DOI":"10.1128\/JVI.05193-11","volume":"85","author":"M Terajima","year":"2011","unstructured":"Terajima M, Cruz J, Co MDT et al (2011) Complement-dependent lysis of influenza a virus-infected cells by broadly cross-reactive human monoclonal antibodies. J Virol 85:13463. https:\/\/doi.org\/10.1128\/JVI.05193-11","journal-title":"J Virol"},{"key":"5074_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02177","author":"B Schiela","year":"2018","unstructured":"Schiela B, Bernklau S, Malekshahi Z et al (2018) Active human complement reduces the Zika virus load via formation of the membrane-attack complex. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2018.02177","journal-title":"Front Immunol"},{"key":"5074_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01450","author":"J Mellors","year":"2020","unstructured":"Mellors J, Tipton T, Longet S, Carroll M (2020) Viral evasion of the complement system and its importance for vaccines and therapeutics. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2020.01450","journal-title":"Front Immunol"},{"key":"5074_CR15","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1084\/jem.175.6.1547","volume":"175","author":"TJ Oglesby","year":"1992","unstructured":"Oglesby TJ, Allen CJ, Liszewski MK et al (1992) Membrane cofactor protein (CD46) protects cells from complement- mediated attack by an intrinsic mechanism. J Exp Med 175:1547\u20131551","journal-title":"J Exp Med"},{"key":"5074_CR16","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1084\/jem.160.5.1558","volume":"160","author":"ME Medof","year":"1984","unstructured":"Medof ME, Kinoshita T, Nussenzweig V (1984) Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med 160:1558\u20131578","journal-title":"J Exp Med"},{"key":"5074_CR17","first-page":"1","volume":"71","author":"S Meri","year":"1990","unstructured":"Meri S, Morgan BP, Davies A et al (1990) Human protectin (CD59), an 18000\u201320000 MW complement lysis restricting factor, inhibits C5b\u20138 catalysed insertion of C9 into lipid bilayers. Immunology 71:1\u20139","journal-title":"Immunology"},{"key":"5074_CR18","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1172\/JCI109527","volume":"64","author":"MM Glovsky","year":"1979","unstructured":"Glovsky MM, Hugli TE, Ishizaka T et al (1979) Anaphylatoxin-induced histamine release with human leukocytes: studies of C3a leukocyte binding and histamine release. J Clin Invest 64:804\u2013811. https:\/\/doi.org\/10.1172\/JCI109527","journal-title":"J Clin Invest"},{"key":"5074_CR19","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1172\/JCI113403","volume":"81","author":"ES Schulman","year":"1988","unstructured":"Schulman ES, Post TJ, Henson PM, Giclas PC (1988) Differential effects of the complement peptides, C5a and C5a des Arg on human basophil and lung mast cell histamine release. J Clin Invest 81:918\u2013923. https:\/\/doi.org\/10.1172\/JCI113403","journal-title":"J Clin Invest"},{"key":"5074_CR20","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.4049\/jimmunol.156.9.3455","volume":"156","author":"T Takabayashi","year":"1996","unstructured":"Takabayashi T, Vannier E, Clark BD et al (1996) A new biologic role for C3a and C3a desArg: regulation of TNF-alpha and IL-1 beta synthesis. J Immunol 156:3455\u20133460","journal-title":"J Immunol"},{"key":"5074_CR21","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/eji.1830240304","volume":"24","author":"J Elsner","year":"1994","unstructured":"Elsner J, Oppermann M, Czech W et al (1994) C3a activates reactive oxygen radical species production and intracellular calcium transients in human eosinophils. Eur J Immunol 24:518\u2013522. https:\/\/doi.org\/10.1002\/eji.1830240304","journal-title":"Eur J Immunol"},{"key":"5074_CR22","doi-asserted-by":"publisher","first-page":"6132","DOI":"10.4049\/jimmunol.180.9.6132","volume":"180","author":"M Takahashi","year":"2008","unstructured":"Takahashi M, Iwaki D, Kanno K et al (2008) Mannose-binding lectin (MBL)-associated serine protease (MASP)-1 contributes to activation of the lectin complement pathway. J Immunol 180:6132\u20136138","journal-title":"J Immunol"},{"key":"5074_CR23","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1126\/science.287.5458.1664","volume":"287","author":"JA Wilson","year":"2000","unstructured":"Wilson JA, Hevey M, Bakken R et al (2000) Epitopes involved in antibody-mediated protection from Ebola virus. Science 287:1664\u20131666. https:\/\/doi.org\/10.1126\/science.287.5458.1664","journal-title":"Science"},{"key":"5074_CR24","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1128\/JVI.76.3.1369-1378.2002","volume":"76","author":"JQ Feng","year":"2002","unstructured":"Feng JQ, Mozdzanowska K, Gerhard W (2002) Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype. J Virol 76:1369\u20131378. https:\/\/doi.org\/10.1128\/JVI.76.3.1369-1378.2002","journal-title":"J Virol"},{"key":"5074_CR25","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1128\/JVI.02128-06","volume":"81","author":"JP Jayasekera","year":"2007","unstructured":"Jayasekera JP, Moseman EA, Carroll MC (2007) Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity. J Virol 81:3487\u20133494. https:\/\/doi.org\/10.1128\/JVI.02128-06","journal-title":"J Virol"},{"key":"5074_CR26","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1073\/pnas.64.2.520","volume":"64","author":"WD Linscott","year":"1969","unstructured":"Linscott WD, Levinson WE (1969) Complement components required for virus neutralization by early immunoglobulin antibody. Proc Natl Acad Sci U S A 64:520\u2013527. https:\/\/doi.org\/10.1073\/pnas.64.2.520","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5074_CR27","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1084\/jem.140.2.549","volume":"140","author":"MBA Oldstone","year":"1974","unstructured":"Oldstone MBA, Cooper NR, Larson DL (1974) Formation and biologic role of polyoma virus-antibody complexes: a critical role for complement. J Exp Med 140:549\u2013565. https:\/\/doi.org\/10.1084\/jem.140.2.549","journal-title":"J Exp Med"},{"key":"5074_CR28","doi-asserted-by":"publisher","first-page":"eabn9243","DOI":"10.1126\/scitranslmed.abn9243","volume":"14","author":"YC Bartsch","year":"2022","unstructured":"Bartsch YC, Tong X, Kang J et al (2022) Omicron variant Spike-specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines. Sci Transl Med 14:eabn9243. https:\/\/doi.org\/10.1126\/scitranslmed.abn9243","journal-title":"Sci Transl Med"},{"key":"5074_CR29","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.4049\/jimmunol.107.6.1618","volume":"107","author":"BJ Graham","year":"1971","unstructured":"Graham BJ, Minamishima Y, Dreesman GR et al (1971) Complement-requiring neutralizing antibodies in hyperimmune sera to human cytomegaloviruses1. J Immunol 107:1618\u20131630. https:\/\/doi.org\/10.4049\/jimmunol.107.6.1618","journal-title":"J Immunol"},{"key":"5074_CR30","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1128\/iai.21.1.151-157.1978","volume":"21","author":"JL Waner","year":"1978","unstructured":"Waner JL, Weller TH (1978) Analysis of antigenic diversity among human cytomegaloviruses by kinetic neutralization tests with high-titered rabbit antisera. Infect Immun 21:151\u2013157. https:\/\/doi.org\/10.1128\/iai.21.1.151-157.1978","journal-title":"Infect Immun"},{"key":"5074_CR31","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1002\/j.1460-2075.1986.tb04606.x","volume":"5","author":"MP Cranage","year":"1986","unstructured":"Cranage MP, Kouzarides T, Bankier AT et al (1986) Identification of the human cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus. EMBO J 5:3057\u20133063","journal-title":"EMBO J"},{"key":"5074_CR32","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1080\/21645515.2016.1164376","volume":"12","author":"AC Finnefrock","year":"2016","unstructured":"Finnefrock AC, Freed DC, Tang A et al (2016) Preclinical evaluations of peptide-conjugate vaccines targeting the antigenic domain-2 of glycoprotein B of human cytomegalovirus. Hum Vaccin Immunother 12:2106\u20132112. https:\/\/doi.org\/10.1080\/21645515.2016.1164376","journal-title":"Hum Vaccin Immunother"},{"key":"5074_CR33","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1086\/514050","volume":"176","author":"OB Spiller","year":"1997","unstructured":"Spiller OB, Hanna SM, Devine DV, Tufaro F (1997) Neutralization of cytomegalovirus virions: the role of complement. J Infect Dis 176:339\u2013347. https:\/\/doi.org\/10.1086\/514050","journal-title":"J Infect Dis"},{"key":"5074_CR34","doi-asserted-by":"publisher","first-page":"5580","DOI":"10.1016\/j.vaccine.2018.07.056","volume":"36","author":"X Cui","year":"2018","unstructured":"Cui X, Cao Z, Wang S et al (2018) Novel trimeric human cytomegalovirus glycoprotein B elicits a high-titer neutralizing antibody response. Vaccine 36:5580\u20135590. https:\/\/doi.org\/10.1016\/j.vaccine.2018.07.056","journal-title":"Vaccine"},{"key":"5074_CR35","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.3390\/ijms20133158","volume":"20","author":"X Cui","year":"2019","unstructured":"Cui X, Cao Z, Wang S et al (2019) Immunization of rabbits with recombinant human cytomegalovirus trimeric versus monomeric gH\/gL protein elicits markedly higher titers of antibody and neutralization activity. Int J Mol Sci 20:3158. https:\/\/doi.org\/10.3390\/ijms20133158","journal-title":"Int J Mol Sci"},{"key":"5074_CR36","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.vaccine.2012.12.009","volume":"31","author":"RJ Loomis","year":"2013","unstructured":"Loomis RJ, Lilja AE, Monroe J et al (2013) Vectored co-delivery of human cytomegalovirus gH and gL proteins elicits potent complement-independent neutralizing antibodies. Vaccine 31:919\u2013926. https:\/\/doi.org\/10.1016\/j.vaccine.2012.12.009","journal-title":"Vaccine"},{"key":"5074_CR37","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3181\/00379727-124-31692","volume":"124","author":"WE Rawls","year":"1967","unstructured":"Rawls WE, Desmyter J, Melnick JL (1967) Rubella virus neutralization by plaque reduction. Proc Soc Exp Biol Med 124:167\u2013172. https:\/\/doi.org\/10.3181\/00379727-124-31692","journal-title":"Proc Soc Exp Biol Med"},{"key":"5074_CR38","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1093\/infdis\/139.4.432","volume":"139","author":"C Grose","year":"1979","unstructured":"Grose C, Edmond BJ, Brunell PA (1979) Complement-enhanced neutralizing antibody response to varicella-zoster virus. J Infect Dis 139:432\u2013437. https:\/\/doi.org\/10.1093\/infdis\/139.4.432","journal-title":"J Infect Dis"},{"key":"5074_CR39","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1128\/jcm.12.3.426-432.1980","volume":"12","author":"AL Frank","year":"1980","unstructured":"Frank AL, Puck J, Hughes BJ, Cate TR (1980) Microneutralization test for influenza A and B and parainfluenza 1 and 2 viruses that uses continuous cell lines and fresh serum enhancement. J Clin Microbiol 12:426\u2013432. https:\/\/doi.org\/10.1128\/jcm.12.3.426-432.1980","journal-title":"J Clin Microbiol"},{"key":"5074_CR40","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.cell.2016.09.049","volume":"167","author":"I Gilchuk","year":"2016","unstructured":"Gilchuk I, Gilchuk P, Sapparapu G et al (2016) Cross-neutralizing and protective human antibody specificities to poxvirus infections. Cell 167:684-694.e9. https:\/\/doi.org\/10.1016\/j.cell.2016.09.049","journal-title":"Cell"},{"key":"5074_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0214467","volume":"14","author":"TP Blevins","year":"2019","unstructured":"Blevins TP, Yu Y, Belshe RB et al (2019) Correlation between herpes simplex virus neutralizing antibody titers determined by ELVIS cell and traditional plaque reduction assays. PLoS ONE 14:e0214467. https:\/\/doi.org\/10.1371\/journal.pone.0214467","journal-title":"PLoS ONE"},{"key":"5074_CR42","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1093\/infdis\/jix584","volume":"217","author":"AW Rimoin","year":"2018","unstructured":"Rimoin AW, Lu K, Bramble MS et al (2018) Ebola virus neutralizing antibodies detectable in survivors of the Yambuku, Zaire outbreak 40 years after infection. J Infect Dis 217:223\u2013231. https:\/\/doi.org\/10.1093\/infdis\/jix584","journal-title":"J Infect Dis"},{"key":"5074_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.857481","author":"J Mellors","year":"2022","unstructured":"Mellors J, Tipton T, Fehling SK et al (2022) Complement-mediated neutralisation identified in Ebola virus disease survivor plasma: implications for protection and pathogenesis. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2022.857481","journal-title":"Front Immunol"},{"key":"5074_CR44","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1038\/s41590-018-0233-9","volume":"19","author":"EO Saphire","year":"2018","unstructured":"Saphire EO, Schendel SL, Gunn BM et al (2018) Antibody-mediated protection against Ebola virus. Nat Immunol 19:1169\u20131178. https:\/\/doi.org\/10.1038\/s41590-018-0233-9","journal-title":"Nat Immunol"},{"key":"5074_CR45","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/BF01378972","volume":"84","author":"A Takenaka","year":"1985","unstructured":"Takenaka A, Gibbs CJ, Gajdusek DC (1985) Antiviral neutralizing antibody to Hantaan virus as determined by plaque reduction technique. Arch Virol 84:197\u2013206. https:\/\/doi.org\/10.1007\/BF01378972","journal-title":"Arch Virol"},{"key":"5074_CR46","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1099\/0022-1317-70-4-819","volume":"70","author":"H Asada","year":"1989","unstructured":"Asada H, Balachandra K, Tamura M et al (1989) Cross-reactive immunity among different serotypes of virus causing haemorrhagic fever with renal syndrome. J Gen Virol 70:819\u2013825. https:\/\/doi.org\/10.1099\/0022-1317-70-4-819","journal-title":"J Gen Virol"},{"key":"5074_CR47","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1006\/viro.1998.9586","volume":"255","author":"JW Hooper","year":"1999","unstructured":"Hooper JW, Kamrud KI, Elgh F et al (1999) DNA vaccination with hantavirus M segment elicits neutralizing antibodies and protects against seoul virus infection. Virology 255:269\u2013278. https:\/\/doi.org\/10.1006\/viro.1998.9586","journal-title":"Virology"},{"key":"5074_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003803","volume":"9","author":"N Haese","year":"2015","unstructured":"Haese N, Brocato RL, Henderson T et al (2015) Antiviral biologic produced in DNA vaccine\/goose platform protects hamsters against hantavirus pulmonary syndrome when administered post-exposure. PLoS Negl Trop Dis 9:e0003803. https:\/\/doi.org\/10.1371\/journal.pntd.0003803","journal-title":"PLoS Negl Trop Dis"},{"key":"5074_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109086","volume":"35","author":"TB Engdahl","year":"2021","unstructured":"Engdahl TB, Kuzmina NA, Ronk AJ et al (2021) Broad and potently neutralizing monoclonal antibodies isolated from human survivors of New World hantavirus infection. Cell Rep 35:109086. https:\/\/doi.org\/10.1016\/j.celrep.2021.109086","journal-title":"Cell Rep"},{"key":"5074_CR50","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.1248943","volume":"343","author":"CA Diebolder","year":"2014","unstructured":"Diebolder CA, Beurskens FJ, de Jong RN et al (2014) Complement is activated by IgG hexamers assembled at the cell surface. Science 343:1260\u20131263. https:\/\/doi.org\/10.1126\/science.1248943","journal-title":"Science"},{"key":"5074_CR51","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1365-3083.1989.tb01225.x","volume":"30","author":"P Garred","year":"1989","unstructured":"Garred P, Michaelsen TE, Aase A (1989) The IgG subclass pattern of complement activation depends on epitope density and antibody and complement concentration. Scand J Immunol 30:379\u2013382. https:\/\/doi.org\/10.1111\/j.1365-3083.1989.tb01225.x","journal-title":"Scand J Immunol"},{"key":"5074_CR52","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/eji.1830210103","volume":"21","author":"TE Michaelsen","year":"1991","unstructured":"Michaelsen TE, Garred P, Aase A (1991) Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration. Eur J Immunol 21:11\u201316. https:\/\/doi.org\/10.1002\/eji.1830210103","journal-title":"Eur J Immunol"},{"key":"5074_CR53","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1128\/JVI.62.4.1416-1422.1988","volume":"62","author":"MP Cranage","year":"1988","unstructured":"Cranage MP, Smith GL, Bell SE et al (1988) Identification and expression of a human cytomegalovirus glycoprotein with homology to the Epstein-Barr virus BXLF2 product, varicella-zoster virus gpIII, and herpes simplex virus type 1 glycoprotein H. J Virol 62:1416\u20131422. https:\/\/doi.org\/10.1128\/JVI.62.4.1416-1422.1988","journal-title":"J Virol"},{"key":"5074_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-017-0038-0","author":"F Li","year":"2017","unstructured":"Li F, Freed DC, Tang A et al (2017) Complement enhances in vitro neutralizing potency of antibodies to human cytomegalovirus glycoprotein B (gB) and immune sera induced by gB\/MF59 vaccination. NPJ Vaccines. https:\/\/doi.org\/10.1038\/s41541-017-0038-0","journal-title":"NPJ Vaccines"},{"key":"5074_CR55","doi-asserted-by":"publisher","first-page":"eaat7796","DOI":"10.1126\/sciimmunol.aat7796","volume":"3","author":"G Lofano","year":"2018","unstructured":"Lofano G, Gorman MJ, Yousif AS et al (2018) Antigen-specific antibody Fc glycosylation enhances humoral immunity via the recruitment of complement. Sci Immunol 3:eaat7796. https:\/\/doi.org\/10.1126\/sciimmunol.aat7796","journal-title":"Sci Immunol"},{"key":"5074_CR56","doi-asserted-by":"publisher","first-page":"e00880-20","DOI":"10.1128\/mSphere.00880-20","volume":"5","author":"M Muenchhoff","year":"2020","unstructured":"Muenchhoff M, Chung AW, Roider J et al (2020) Distinct immunoglobulin Fc glycosylation patterns are associated with disease nonprogression and broadly neutralizing antibody responses in children with HIV infection. mSphere 5:e00880-20. https:\/\/doi.org\/10.1128\/mSphere.00880-20","journal-title":"mSphere"},{"key":"5074_CR57","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.tips.2009.04.007","volume":"30","author":"R Jefferis","year":"2009","unstructured":"Jefferis R (2009) Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharmacol Sci 30:356\u2013362. https:\/\/doi.org\/10.1016\/j.tips.2009.04.007","journal-title":"Trends Pharmacol Sci"},{"key":"5074_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00877","author":"G Dekkers","year":"2017","unstructured":"Dekkers G, Treffers L, Plomp R et al (2017) Decoding the human immunoglobulin G-glycan repertoire reveals a spectrum of Fc-receptor- and complement-mediated-effector activities. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2017.00877","journal-title":"Front Immunol"},{"key":"5074_CR59","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.1128\/jvi.62.9.3309-3318.1988","volume":"62","author":"WJ Britt","year":"1988","unstructured":"Britt WJ, Vugler L, Stephens EB (1988) Induction of complement-dependent and -independent neutralizing antibodies by recombinant-derived human cytomegalovirus gp55-116 (gB). J Virol 62:3309\u20133318. https:\/\/doi.org\/10.1128\/jvi.62.9.3309-3318.1988","journal-title":"J Virol"},{"key":"5074_CR60","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1084\/jem.168.1.127","volume":"168","author":"CI Bindon","year":"1988","unstructured":"Bindon CI, Hale G, Br\u00fcggemann M, Waldmann H (1988) Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J Exp Med 168:127\u2013142. https:\/\/doi.org\/10.1084\/jem.168.1.127","journal-title":"J Exp Med"},{"key":"5074_CR61","doi-asserted-by":"publisher","first-page":"33234","DOI":"10.1074\/jbc.272.52.33234","volume":"272","author":"M Kaul","year":"1997","unstructured":"Kaul M, Loos M (1997) Dissection of C1q capability of interacting with IgG time-dependent formation of a tight and only partly reversible association. J Biol Chem 272:33234\u201333244. https:\/\/doi.org\/10.1074\/jbc.272.52.33234","journal-title":"J Biol Chem"},{"key":"5074_CR62","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2102787118","volume":"118","author":"SA Zwarthoff","year":"2021","unstructured":"Zwarthoff SA, Widmer K, Kuipers A et al (2021) C1q binding to surface-bound IgG is stabilized by C1r2s2 proteases. Proc Natl Acad Sci 118:e2102787118. https:\/\/doi.org\/10.1073\/pnas.2102787118","journal-title":"Proc Natl Acad Sci"},{"key":"5074_CR63","doi-asserted-by":"publisher","first-page":"958","DOI":"10.3389\/fimmu.2018.00958","volume":"9","author":"G-M Lilienthal","year":"2018","unstructured":"Lilienthal G-M, Rahm\u00f6ller J, Petry J et al (2018) Potential of murine IgG1 and human IgG4 to inhibit the classical complement and Fc\u03b3 Receptor activation pathways. Front Immunol 9:958. https:\/\/doi.org\/10.3389\/fimmu.2018.00958","journal-title":"Front Immunol"},{"key":"5074_CR64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020597","volume":"6","author":"ME Cohen","year":"2011","unstructured":"Cohen ME, Xiao Y, Eisenberg RJ et al (2011) Antibody against extracellular vaccinia Virus (EV) protects mice through complement and Fc receptors. PLoS ONE 6:e20597. https:\/\/doi.org\/10.1371\/journal.pone.0020597","journal-title":"PLoS ONE"},{"key":"5074_CR65","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1128\/JVI.01797-08","volume":"83","author":"MR-E-I Benhnia","year":"2009","unstructured":"Benhnia MR-E-I, McCausland MM, Moyron J et al (2009) Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement. J Virol 83:1201\u20131215. https:\/\/doi.org\/10.1128\/JVI.01797-08","journal-title":"J Virol"},{"key":"5074_CR66","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1099\/0022-1317-3-1-97","volume":"3","author":"DM Berry","year":"1968","unstructured":"Berry DM, Almeida JD (1968) The morphological and biological effects of various antisera on avian infectious bronchitis virus. J Gen Virol 3:97\u2013102. https:\/\/doi.org\/10.1099\/0022-1317-3-1-97","journal-title":"J Gen Virol"},{"key":"5074_CR67","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1128\/jvi.55.2.274-280.1985","volume":"55","author":"L Rasmussen","year":"1985","unstructured":"Rasmussen L, Mullenax J, Nelson R, Merigan TC (1985) Viral polypeptides detected by a complement-dependent neutralizing murine monoclonal antibody to human cytomegalovirus. J Virol 55:274\u2013280. https:\/\/doi.org\/10.1128\/jvi.55.2.274-280.1985","journal-title":"J Virol"},{"key":"5074_CR68","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.micinf.2009.07.010","volume":"11","author":"A Ohta","year":"2009","unstructured":"Ohta A, Fujita A, Murayama T et al (2009) Recombinant human monoclonal antibodies to human cytomegalovirus glycoprotein B neutralize virus in a complement-dependent manner. Microbes Infect 11:1029\u20131036. https:\/\/doi.org\/10.1016\/j.micinf.2009.07.010","journal-title":"Microbes Infect"},{"key":"5074_CR69","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1172\/jci110696","volume":"70","author":"GR Nemerow","year":"1982","unstructured":"Nemerow GR, Jensen FC, Cooper NR (1982) Neutralization of Epstein-Barr virus by nonimmune human serum. Role of cross-reacting antibody to herpes simplex virus and complement. J Clin Invest 70:1081\u20131091. https:\/\/doi.org\/10.1172\/jci110696","journal-title":"J Clin Invest"},{"key":"5074_CR70","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1099\/0022-1317-25-2-229","volume":"25","author":"AI Radwan","year":"1974","unstructured":"Radwan AI, Crawford TB (1974) The mechanisms of neutralization of sensitized equine arteritis virus by complement components. J Gen Virol 25:229\u2013237. https:\/\/doi.org\/10.1099\/0022-1317-25-2-229","journal-title":"J Gen Virol"},{"key":"5074_CR71","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1073\/pnas.65.3.528","volume":"65","author":"CA Daniels","year":"1970","unstructured":"Daniels CA, Borsos T, Rapp HJ et al (1970) Neutralization of sensitized virus by purified components of complement. Proc Natl Acad Sci U S A 65:528\u2013535. https:\/\/doi.org\/10.1073\/pnas.65.3.528","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5074_CR72","doi-asserted-by":"publisher","first-page":"4528","DOI":"10.4049\/jimmunol.165.8.4528","volume":"165","author":"HM Friedman","year":"2000","unstructured":"Friedman HM, Wang L, Pangburn MK et al (2000) Novel mechanism of antibody-independent complement neutralization of herpes simplex virus type 1. J Immunol 165:4528\u20134536. https:\/\/doi.org\/10.4049\/jimmunol.165.8.4528","journal-title":"J Immunol"},{"key":"5074_CR73","doi-asserted-by":"publisher","first-page":"4038","DOI":"10.1128\/JVI.80.8.4038-4046.2006","volume":"80","author":"LM Hook","year":"2006","unstructured":"Hook LM, Lubinski JM, Jiang M et al (2006) Herpes simplex virus type 1 and 2 glycoprotein c prevents complement-mediated neutralization induced by natural immunoglobulin M antibody. J Virol 80:4038\u20134046. https:\/\/doi.org\/10.1128\/JVI.80.8.4038-4046.2006","journal-title":"J Virol"},{"key":"5074_CR74","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.4049\/jimmunol.130.3.1317","volume":"130","author":"DP Beebe","year":"1983","unstructured":"Beebe DP, Schreiber RD, Cooper NR (1983) Neutralization of influenza virus by normal human sera: mechanisms involving antibody and complement. J Immunol 130:1317\u20131322. https:\/\/doi.org\/10.4049\/jimmunol.130.3.1317","journal-title":"J Immunol"},{"key":"5074_CR75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088735","volume":"9","author":"M Page","year":"2014","unstructured":"Page M, Quartey-Papafio R, Robinson M et al (2014) Complement-mediated virus infectivity neutralisation by HLA antibodies is associated with sterilising immunity to SIV challenge in the macaque model for HIV\/AIDS. PLoS ONE 9:e88735. https:\/\/doi.org\/10.1371\/journal.pone.0088735","journal-title":"PLoS ONE"},{"key":"5074_CR76","doi-asserted-by":"publisher","first-page":"28","DOI":"10.4049\/jimmunol.118.1.28","volume":"118","author":"JP Leddy","year":"1977","unstructured":"Leddy JP, Simons RL, Douglas RG (1977) Effect of selective complement deficiency on the rate of neutralization of enveloped viruses by human sera1. J Immunol 118:28\u201334. https:\/\/doi.org\/10.4049\/jimmunol.118.1.28","journal-title":"J Immunol"},{"key":"5074_CR77","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.virol.2004.07.024","volume":"328","author":"S Lustig","year":"2004","unstructured":"Lustig S, Fogg C, Whitbeck JC, Moss B (2004) Synergistic neutralizing activities of antibodies to outer membrane proteins of the two infectious forms of vaccinia virus in the presence of complement. Virology 328:30\u201335. https:\/\/doi.org\/10.1016\/j.virol.2004.07.024","journal-title":"Virology"},{"key":"5074_CR78","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.4049\/jimmunol.126.4.1562","volume":"126","author":"DP Beebe","year":"1981","unstructured":"Beebe DP, Cooper NR (1981) Neutralization of vesicular stomatitis virus (VSV) by human complement requires a natural IgM antibody present in human serum. J Immunol 126:1562\u20131568. https:\/\/doi.org\/10.4049\/jimmunol.126.4.1562","journal-title":"J Immunol"},{"key":"5074_CR79","volume-title":"Immunobiology: the immune system in health and disease","author":"CJ Janeway","year":"2001","unstructured":"Janeway CJ, Travers P, Walport M, Shlomchik MJ (2001) The complement system and innate immunity. Immunobiology: the immune system in health and disease, 5th edn. Garland Science","edition":"5"},{"key":"5074_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2017.01117","author":"P Agrawal","year":"2017","unstructured":"Agrawal P, Nawadkar R, Ojha H et al (2017) Complement evasion strategies of viruses: an overview. Front Microbiol. https:\/\/doi.org\/10.3389\/fmicb.2017.01117","journal-title":"Front Microbiol"},{"key":"5074_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1099\/vir.0.18709-0","volume":"84","author":"HW Favoreel","year":"2003","unstructured":"Favoreel HW, Van de Walle GR, Nauwynck HJ, Pensaert MB (2003) Virus complement evasion strategies. J Gen Virol 84:1\u201315. https:\/\/doi.org\/10.1099\/vir.0.18709-0","journal-title":"J Gen Virol"},{"key":"5074_CR82","doi-asserted-by":"publisher","first-page":"1256070","DOI":"10.1126\/science.1256070","volume":"345","author":"JCH Tam","year":"2014","unstructured":"Tam JCH, Bidgood SR, McEwan WA, James LC (2014) Intracellular sensing of complement C3 activates cell autonomous immunity. Science 345:1256070. https:\/\/doi.org\/10.1126\/science.1256070","journal-title":"Science"},{"key":"5074_CR83","doi-asserted-by":"publisher","first-page":"20160221","DOI":"10.1098\/rstb.2016.0221","volume":"372","author":"C Bayly-Jones","year":"2017","unstructured":"Bayly-Jones C, Bubeck D, Dunstone MA (2017) The mystery behind membrane insertion: a review of the complement membrane attack complex. Philos Trans R Soc B Biol Sci 372:20160221. https:\/\/doi.org\/10.1098\/rstb.2016.0221","journal-title":"Philos Trans R Soc B Biol Sci"},{"key":"5074_CR84","doi-asserted-by":"publisher","first-page":"5316","DOI":"10.1038\/s41467-018-07653-5","volume":"9","author":"A Menny","year":"2018","unstructured":"Menny A, Serna M, Boyd CM et al (2018) CryoEM reveals how the complement membrane attack complex ruptures lipid bilayers. Nat Commun 9:5316. https:\/\/doi.org\/10.1038\/s41467-018-07653-5","journal-title":"Nat Commun"},{"key":"5074_CR85","doi-asserted-by":"publisher","first-page":"3816","DOI":"10.1073\/pnas.80.12.3816","volume":"80","author":"CL Koski","year":"1983","unstructured":"Koski CL, Ramm LE, Hammer CH et al (1983) Cytolysis of nucleated cells by complement: cell death displays multi-hit characteristics. Proc Natl Acad Sci U S A 80:3816\u20133820. https:\/\/doi.org\/10.1073\/pnas.80.12.3816","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5074_CR86","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1093\/intimm\/dxh300","volume":"17","author":"D Pilzer","year":"2005","unstructured":"Pilzer D, Fishelson Z (2005) Mortalin\/GRP75 promotes release of membrane vesicles from immune attacked cells and protection from complement-mediated lysis. Int Immunol 17:1239\u20131248. https:\/\/doi.org\/10.1093\/intimm\/dxh300","journal-title":"Int Immunol"},{"key":"5074_CR87","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.4049\/jimmunol.138.5.1530","volume":"138","author":"SH Kim","year":"1987","unstructured":"Kim SH, Carney DF, Hammer CH, Shin ML (1987) Nucleated cell killing by complement: effects of C5b\u20139 channel size and extracellular Ca2+ on the lytic process. J Immunol 138:1530\u20131536","journal-title":"J Immunol"},{"key":"5074_CR88","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/1521-4141(200203)32:3<783::AID-IMMU783>3.0.CO;2-Q","volume":"32","author":"AJ Nauta","year":"2002","unstructured":"Nauta AJ, Daha MR, Tijsma O et al (2002) The membrane attack complex of complement induces caspase activation and apoptosis. Eur J Immunol 32:783\u2013792. https:\/\/doi.org\/10.1002\/1521-4141(200203)32:3%3c783::AID-IMMU783%3e3.0.CO;2-Q","journal-title":"Eur J Immunol"},{"key":"5074_CR89","doi-asserted-by":"publisher","first-page":"1900074","DOI":"10.1002\/bies.201900074","volume":"41","author":"DJ Doorduijn","year":"2019","unstructured":"Doorduijn DJ, Rooijakkers SHM, Heesterbeek DAC (2019) How the membrane attack complex damages the bacterial cell envelope and kills gram-negative bacteria. BioEssays 41:1900074. https:\/\/doi.org\/10.1002\/bies.201900074","journal-title":"BioEssays"},{"key":"5074_CR90","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1006\/viro.1993.1398","volume":"195","author":"GT Spear","year":"1993","unstructured":"Spear GT, Takefman DM, Sullivan BL et al (1993) Anti-cellular antibodies in sera from vaccinated macaques can induce complement-mediated virolysis of human immunodeficiency virus and simian immunodeficiency virus. Virology 195:475\u2013480. https:\/\/doi.org\/10.1006\/viro.1993.1398","journal-title":"Virology"},{"key":"5074_CR91","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1002079","volume":"7","author":"J Zhao","year":"2011","unstructured":"Zhao J, Wu H, Khosravi M et al (2011) Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PLoS Genet 7:e1002079. https:\/\/doi.org\/10.1371\/journal.pgen.1002079","journal-title":"PLoS Genet"},{"key":"5074_CR92","doi-asserted-by":"publisher","first-page":"571","DOI":"10.5021\/ad.2017.29.5.571","volume":"29","author":"JS Kim","year":"2017","unstructured":"Kim JS, Lee SY, Hahn HJ et al (2017) Association of single-nucleotide polymorphisms of the MBL2 with atopic dermatitis in Korean patients. Ann Dermatol 29:571\u2013577. https:\/\/doi.org\/10.5021\/ad.2017.29.5.571","journal-title":"Ann Dermatol"},{"key":"5074_CR93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02664","author":"M Gaya da Costa","year":"2018","unstructured":"Gaya da Costa M, Poppelaars F, van Kooten C et al (2018) Age and sex-associated changes of complement activity and complement levels in a healthy caucasian population. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2018.02664","journal-title":"Front Immunol"},{"key":"5074_CR94","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/978-1-0716-1900-1_18","volume":"2414","author":"F Alexander","year":"2022","unstructured":"Alexander F, Brunt E, Humphries H et al (2022) Generation of a universal human complement source by large-scale depletion of IgG and IgM from pooled human plasma. Methods Mol Biol 2414:341\u2013362. https:\/\/doi.org\/10.1007\/978-1-0716-1900-1_18","journal-title":"Methods Mol Biol"},{"key":"5074_CR95","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.vetimm.2018.03.008","volume":"199","author":"S Nayak","year":"2018","unstructured":"Nayak S, Portugal I, Zilberg D (2018) Analyzing complement activity in the serum and body homogenates of different fish species, using rabbit and sheep red blood cells. Vet Immunol Immunopathol 199:39\u201342. https:\/\/doi.org\/10.1016\/j.vetimm.2018.03.008","journal-title":"Vet Immunol Immunopathol"},{"key":"5074_CR96","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0049147","volume":"7","author":"CM O\u2019Shaughnessy","year":"2012","unstructured":"O\u2019Shaughnessy CM, Cunningham AF, MacLennan CA (2012) The stability of complement-mediated bactericidal activity in human serum against salmonella. PLoS ONE 7:e49147. https:\/\/doi.org\/10.1371\/journal.pone.0049147","journal-title":"PLoS ONE"},{"key":"5074_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-021-00286-8","volume":"6","author":"A Kleinschmidt","year":"2021","unstructured":"Kleinschmidt A, Vadivelu K, Serino L et al (2021) Endogenous complement human serum bactericidal assay (enc-hSBA) for vaccine effectiveness assessments against meningococcal serogroup B. NPJ Vaccines 6:1\u20138. https:\/\/doi.org\/10.1038\/s41541-021-00286-8","journal-title":"NPJ Vaccines"},{"key":"5074_CR98","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/j.1348-0421.1996.tb01109.x","volume":"40","author":"M Nakamura","year":"1996","unstructured":"Nakamura M, Okada H, Sasaki H et al (1996) Quantification of the CD55 and CD59, membrane inhibitors of complement on HIV-1 particles as a function of complement-mediated virolysis. Microbiol Immunol 40:561\u2013567. https:\/\/doi.org\/10.1111\/j.1348-0421.1996.tb01109.x","journal-title":"Microbiol Immunol"},{"key":"5074_CR99","doi-asserted-by":"publisher","first-page":"9929","DOI":"10.1128\/JVI.01154-12","volume":"86","author":"JB Johnson","year":"2012","unstructured":"Johnson JB, Lyles DS, Alexander-Miller MA, Parks GD (2012) Virion-associated complement regulator CD55 is more potent than CD46 in mediating resistance of mumps virus and vesicular stomatitis virus to neutralization. J Virol 86:9929\u20139940. https:\/\/doi.org\/10.1128\/JVI.01154-12","journal-title":"J Virol"},{"key":"5074_CR100","doi-asserted-by":"publisher","first-page":"510","DOI":"10.3390\/v13030510","volume":"13","author":"Z Malekshahi","year":"2021","unstructured":"Malekshahi Z, Bernklau S, Schiela B et al (2021) Incorporation of CD55 into the Zika viral envelope contributes to its stability against human complement. Viruses 13:510. https:\/\/doi.org\/10.3390\/v13030510","journal-title":"Viruses"},{"key":"5074_CR101","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/030089167706300108","volume":"63","author":"S M\u00e9nard","year":"1977","unstructured":"M\u00e9nard S, Colnaghi MI (1977) Analysis of rabbit and guinea pig complement efficiency in cytotoxicity tests against fibrosarcoma and lymphosarcoma cells. Tumori 63:59\u201368. https:\/\/doi.org\/10.1177\/030089167706300108","journal-title":"Tumori"},{"key":"5074_CR102","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/1521-4141(200206)32:6<1802::AID-IMMU1802>3.0.CO;2-C","volume":"32","author":"C Collins","year":"2002","unstructured":"Collins C, Tsui FWL, Shulman MJ (2002) Differential activation of human and guinea pig complement by pentameric and hexameric IgM. Eur J Immunol 32:1802\u20131810. https:\/\/doi.org\/10.1002\/1521-4141(200206)32:6%3c1802::AID-IMMU1802%3e3.0.CO;2-C","journal-title":"Eur J Immunol"},{"key":"5074_CR103","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.03789-22","author":"J Merluza","year":"2023","unstructured":"Merluza J, Ung J, Makowski K et al (2023) Validation and establishment of the SARS-CoV-2 lentivirus surrogate neutralization assay as a prescreening tool for the plaque reduction neutralization test. Microbiol Spectr. https:\/\/doi.org\/10.1128\/spectrum.03789-22","journal-title":"Microbiol Spectr"},{"key":"5074_CR104","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1128\/jvi.76.5.2150-2158.2002","volume":"76","author":"K Meyer","year":"2002","unstructured":"Meyer K, Basu A, Przysiecki CT et al (2002) Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C virus E2 chimeric glycoprotein. J Virol 76:2150\u20132158. https:\/\/doi.org\/10.1128\/jvi.76.5.2150-2158.2002","journal-title":"J Virol"},{"key":"5074_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.micres.2022.126993","volume":"258","author":"Q Xiang","year":"2022","unstructured":"Xiang Q, Li L, Wu J et al (2022) Application of pseudovirus system in the development of vaccine, antiviral-drugs, and neutralizing antibodies. Microbiol Res 258:126993. https:\/\/doi.org\/10.1016\/j.micres.2022.126993","journal-title":"Microbiol Res"},{"key":"5074_CR106","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1177\/1535370216675772","volume":"242","author":"H Abou-El-Hassan","year":"2017","unstructured":"Abou-El-Hassan H, Zaraket H (2017) Viral-derived complement inhibitors: current status and potential role in immunomodulation. Exp Biol Med (Maywood) 242:397\u2013410. https:\/\/doi.org\/10.1177\/1535370216675772","journal-title":"Exp Biol Med (Maywood)"},{"key":"5074_CR107","doi-asserted-by":"publisher","first-page":"L790","DOI":"10.1152\/ajplung.2000.279.5.L790","volume":"279","author":"WT Watford","year":"2000","unstructured":"Watford WT, Ghio AJ, Wright JR (2000) Complement-mediated host defense in the lung. Am J Physiol Lung Cell Mol Physiol 279:L790\u2013L798. https:\/\/doi.org\/10.1152\/ajplung.2000.279.5.L790","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"5074_CR108","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41385-022-00534-7","volume":"15","author":"N Chaudhary","year":"2022","unstructured":"Chaudhary N, Jayaraman A, Reinhardt C et al (2022) A single-cell lung atlas of complement genes identifies the mesothelium and epithelium as prominent sources of extrahepatic complement proteins. Mucosal Immunol 15:927\u2013939. https:\/\/doi.org\/10.1038\/s41385-022-00534-7","journal-title":"Mucosal Immunol"},{"key":"5074_CR109","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1172\/JCI113472","volume":"81","author":"RC Strunk","year":"1988","unstructured":"Strunk RC, Eidlen DM, Mason RJ (1988) Pulmonary alveolar type II epithelial cells synthesize and secrete proteins of the classical and alternative complement pathways. J Clin Invest 81:1419\u20131426. https:\/\/doi.org\/10.1172\/JCI113472","journal-title":"J Clin Invest"},{"key":"5074_CR110","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.4049\/jimmunol.175.5.3150","volume":"175","author":"Y Liu","year":"2005","unstructured":"Liu Y, Endo Y, Iwaki D et al (2005) Human M-ficolin is a secretory protein that activates the lectin complement pathway. J Immunol 175:3150\u20133156. https:\/\/doi.org\/10.4049\/jimmunol.175.5.3150","journal-title":"J Immunol"},{"key":"5074_CR111","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/cei.12952","volume":"188","author":"R Lubbers","year":"2017","unstructured":"Lubbers R, van Essen MF, van Kooten C, Trouw LA (2017) Production of complement components by cells of the immune system. Clin Exp Immunol 188:183\u2013194. https:\/\/doi.org\/10.1111\/cei.12952","journal-title":"Clin Exp Immunol"},{"key":"5074_CR112","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3389\/fimmu.2016.00085","volume":"7","author":"MP Reichhardt","year":"2016","unstructured":"Reichhardt MP, Meri S (2016) SALSA: a regulator of the early steps of complement activation on mucosal surfaces. Front Immunol 7:85","journal-title":"Front Immunol"},{"key":"5074_CR113","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1023\/A:1027320425291","volume":"17","author":"A Andoh","year":"1997","unstructured":"Andoh A, Fujiyama Y, Kimura T et al (1997) Molecular characterization of complement components (C3, C4, and Factor B) in human saliva. J Clin Immunol 17:404\u2013407. https:\/\/doi.org\/10.1023\/A:1027320425291","journal-title":"J Clin Immunol"},{"key":"5074_CR114","doi-asserted-by":"publisher","first-page":"e991","DOI":"10.1016\/j.ijid.2010.06.009","volume":"14","author":"V Hutse","year":"2010","unstructured":"Hutse V, Van Hecke K, De Bruyn R et al (2010) Oral fluid for the serological and molecular diagnosis of measles. Int J Infect Dis 14:e991\u2013e997. https:\/\/doi.org\/10.1016\/j.ijid.2010.06.009","journal-title":"Int J Infect Dis"},{"key":"5074_CR115","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.880154","volume":"13","author":"S Yu","year":"2022","unstructured":"Yu S, Zhang P, Liao M et al (2022) Detection of SARS-CoV-2 specific antibodies in saliva samples. Front Immunol 13:880154. https:\/\/doi.org\/10.3389\/fimmu.2022.880154","journal-title":"Front Immunol"},{"key":"5074_CR116","doi-asserted-by":"publisher","first-page":"ofw031","DOI":"10.1093\/ofid\/ofw031","volume":"3","author":"T Lambe","year":"2016","unstructured":"Lambe T, Rampling T, Samuel D et al (2016) Detection of vaccine-induced antibodies to ebola virus in oral fluid. Open Forum Infect Dis 3:ofw031. https:\/\/doi.org\/10.1093\/ofid\/ofw031","journal-title":"Open Forum Infect Dis"},{"key":"5074_CR117","doi-asserted-by":"publisher","DOI":"10.3402\/jom.v5i0.20401.10.3402\/jom.v5i0.20401","author":"P Brandtzaeg","year":"2013","unstructured":"Brandtzaeg P (2013) Secretory immunity with special reference to the oral cavity. J Oral Microbiol. https:\/\/doi.org\/10.3402\/jom.v5i0.20401.10.3402\/jom.v5i0.20401","journal-title":"J Oral Microbiol"},{"key":"5074_CR118","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/eji.1830170304","volume":"17","author":"PS Hiemstra","year":"1987","unstructured":"Hiemstra PS, Gorter A, Stuurman ME et al (1987) Activation of the alternative pathway of complement by human serum IgA. Eur J Immunol 17:321\u2013326. https:\/\/doi.org\/10.1002\/eji.1830170304","journal-title":"Eur J Immunol"},{"key":"5074_CR119","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1365-3083.1989.tb01199.x","volume":"30","author":"MW Russell","year":"1989","unstructured":"Russell MW, Mansa B (1989) Complement-fixing properties of human IgA antibodies. Alternative pathway complement activation by plastic-bound, but not specific antigen-bound. IgA Scand J Immunol 30:175\u2013183. https:\/\/doi.org\/10.1111\/j.1365-3083.1989.tb01199.x","journal-title":"IgA Scand J Immunol"},{"key":"5074_CR120","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.4049\/jimmunol.167.5.2861","volume":"167","author":"A Roos","year":"2001","unstructured":"Roos A, Bouwman LH, van Gijlswijk-Janssen DJ et al (2001) Human IgA activates the complement system via the mannan-binding lectin pathway1. J Immunol 167:2861\u20132868. https:\/\/doi.org\/10.4049\/jimmunol.167.5.2861","journal-title":"J Immunol"},{"key":"5074_CR121","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1681\/ASN.2006040388","volume":"17","author":"BD Oortwijn","year":"2006","unstructured":"Oortwijn BD, Roos A, Royle L et al (2006) Differential glycosylation of polymeric and monomeric IgA: a possible role in glomerular inflammation in IgA nephropathy. J Am Soc Nephrol 17:3529. https:\/\/doi.org\/10.1681\/ASN.2006040388","journal-title":"J Am Soc Nephrol"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-023-05074-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-023-05074-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-023-05074-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T04:44:44Z","timestamp":1704948284000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-023-05074-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,11]]},"references-count":121,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["5074"],"URL":"https:\/\/doi.org\/10.1007\/s00018-023-05074-2","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,11]]},"assertion":[{"value":"28 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}